PubMed Health⌕ Search

Biomedical subjects

E Woodman

Publications and source records attributed to E Woodman.

7 recordsLinked to original sources
PubMed1985

Prescribing--a case for prolonged treatment.

In an earlier study it was shown that general practitioners changed some of their prescribing habits when they were given detailed analyses of their prescriptions every six months for two years and provided with opportunities to discuss the information with participating colleagues. A follow-up study of the same doctors two years later revealed that most of the effects of the intervention had disappeared, though the increase in generic prescribing persisted. It is concluded that a more sustained intervention is needed to bring about more lasting change.

Drug Prescriptions↗
PubMed1980

Treatment of Salmonella gastroenteritis with ampicillin, amoxicillin, or placebo.

In a randomized, prospective, double-blind study infants and children with uncomplicated Salmonella gastroenteritis were treated with ampicillin (15 patients), amoxicillin (15 patients), or placebo (14 patients). The dosage of antibiotics was 100 mg/kg/day in four equally divided doses given for five days. There was no significant benefit from antibiotic therapy on the duration of diarrhea (means 8.8, 7.3, and 7.2 days, respectively) or on the duration of recovery of Salmonella from stool cultures (means 41.3, 37.0, and 20.9 days, respectively). Bacteriologic relapse was not observed in placebo-treated patients but eight patients given ampicillin (53%) and eight given amoxicillin (53%) had relapse (P = .003). Salmonella isolated in relapse were still susceptible in vitro to the antibiotics. Of the 16 patients with bacteriologic relapse six (38%) had concomitant recurrence of diarrhea. It is concluded that ampicillin or amoxicillin therapy provides no benefit to patients with uncomplicated Salmonella gastroenteritis and substantially increases the risk of bacteriologic and symptomatic relapse.

Amoxicillin↗
PubMed1978

Clinical pharmacology and efficacy of ticarcillin in infants and children.

Ticarcillin was evaluated in 82 neonates and young infants with suspected sepsis and in 16 older children with chronic Pseudomonas infection of the mastoids. The infants also received kanamycin. Individual ticarcillin doses of 75 or 100 mg/kg were given every four, six, or eight hours by intramuscular injection or by a 30-minute intravenous infusion. Mean plasma concentrations one hour after a dose were from 125 to 189 microgram/ml, depending on dosage, age, and maturity. Mean plasma half-lives were approximately 5 hours in the first week of life, 2 hours in infants from 1 to 8 weeks, and 0.9 hours in older children. Volume of distribution was approximately twice as great in infants as in children, and plasma clearance rates correlated inversely with age. Limited efficacy data suggest that ticarcillin is a suitable alternative to ampicillin or carbenicillin, when given concurrently with an aminoglycoside, for newborn infections. When given for several days before mastoidectomy and tympanoplasty, ticarcillin sterilized the mastoids in the majority of patients. A new dosage schedule for ticarcillin in pediatric patients is proposed.

Adolescent↗
PubMed1976

Trimethoprim-sulfamethoxazole therapy for shigellosis.

Twenty-eight infants and children hospitalized for severe shigellosis were treated orally either with ampicillin trihydrate (100 mg/kg/day administered in divided doses every six hours) or with trimethoprim-sulfamethoxazole (trimethoprim, 10 mg; sulfamethoxazole, 50 mg/kg/day in divided doses every 12 hours) for five days. Four patients with ampicillin-resistant shigellae continued to have diarrhea and positive stool cultures during therapy. Patients with susceptible shigellae treated with ampicillin and all patients treated with trimethoprim-sulfamethoxazole responsed promptly and comparably within an average of 1.6 and 1.7 days, respectively, until stool cultures were negative, and 3.1 and 2.9 days, respectively, until diarrhea stopped. Patients with ampicillin-resistant shigellae responded to treatment with trimethoprim-sulfamethoxazole. It is concluded that trimethoprim-sulfamethoxazole is the best currently available drug for treatment of shigellosis in areas where multiple antibiotic resistance of shigellae is common.

Age Factors↗
PubMed1975

Colicin types of Shigella sonnei in relation to antibiotic resistance.

Colicin typing of 436 strains of Shigella sonnei isolated in Dallas during a 10-year period was performed to determine whether resistance to ampicillin was associated with a single strain or was widespread among all S. sonnei types. One hundred ninety-three strains collected during a period of eight and one-half years when ampicillin resistance was 1.6% were available for retrospective review. During the last one and one-half years of study, 20.6% of the 243 strains that represented almost all S. sonnei isolated in Dallas were resistant to ampicillin. More than 50% of the strains collected annually were colicin type 9,22% were untypable, and seven other types were less frequently encountered. Resistance to ampicillin increased slightly from 1.5% to 9.5% among the type 9 strains, and one type 8 strain (2.9%) was resistaiple resistance to seven antibiotics tested was found mainly in untypable strains. Thus it appears that the abrupt increase in ampicillin resistance in mid-1972 was due principally to resistance in a single biotype, and that resistance is not widespread among all types of S. sonnei.

Adult↗